AnnJi Pharmaceutical News
Dedicated to New Drug Development in Dermatology & Neurology
Press Release
Dr. Sophia Wang will Speak at a Webinar Hosted by the Industrial Technology Research Institute (ITRI) on Modern Business Opportunities in New Drug Development
ITRI is to hold a webinar on “Mastering Drug Development Trends and Facing New Biomedical Business Opportunities” on October 14, 2021. Biomedical industry professionals and investors are invited to the lectures and discussion on modern developments and business opportunities of new drug treatment. Dr. Chia Hui (Sophia) Wang from AnnJi will speak at the event
AnnJi to Attend BIO-EUROPE Digital 2021
AnnJi will be attending BIO-EUROPE Digital 2021, Oct 25-28, to meet with potential pharmaceutical partners and present AnnJi’s development programs of novel small molecule drugs in dermatology and neurology. AnnJi looks forward to meeting with you on the online partneringONE® platform (https://partneringone.informaconnect.com/)!
AnnJi to present at BIO Digital International Convention 2021
AnnJi Pharmaceutical Co. is a clinical-stage company focusing on the development of neurological dermatological therapeutics. AnnJi will participate in virtual one-on-one meetings at Digital Bio 2021 held virtually from June 14-18, 2021. The company’s presentation video will be available during the event; featuring AnnJi’s leading assets in the pipeline; such as Nrf2 activator for PolyQ
Merger between AnnJi Pharmaceutical Company (AnnJi) and Allianz Pharmascience (Allianz) gives rise to Taiwan’s leading drug developer in neurodegeneration and dermatology
Merger between AnnJi Pharmaceutical Company (AnnJi) and Allianz Pharmascience (Allianz) gives rise to Taiwan’s leading drug developer in neurodegeneration and dermatology November 23, 2020 – Shareholders of AnnJi and Allianz approved a merger agreement, under which AnnJi will acquire Allianz in a stock for stock transaction. Dr. Wendy Huang, Chairman and CEO of AnnJi commented, “I am
AnnJi is attending BIO-ASIA 2020!
Annji is attending BIO-ASIA 2020! AnnJi is honored to be invited to present our company and pipeline in BIO-ASIA 2020. We are seeking novel drug candidates in that could enrich our pipeline, as well as product development partners for the global market. Please contact us at info@www.ajpharm.com if you are interested in meeting with us.
Positive Feedback of AJ302 from US-FDA reviewers
Positive Feedback of AJ302 from US-FDA reviewers AnnJi received positive feedback from US-FDA to submit an IND to initiate phase 1 clinical trial of AJ302 for the treatment of chemotherapy induced neuropathy. AJ302 is a first-in-class HDAC6 selective inhibitor that has been shown to be safe and effective in ameliorating chemotherapy-induced peripheral neuropathy in animals
Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
